Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BAT6021 |
Synonyms | |
Therapy Description |
BAT6021 is a monoclonal antibody that targets T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and prevents its interaction with its ligands, NECTIN2 (CD112) and PVR (CD155), potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAT6021 | BAT-6021|BAT 6021 | Immune Checkpoint Inhibitor 147 TIGIT Antibody 19 | BAT6021 is a monoclonal antibody that targets T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and prevents its interaction with its ligands, NECTIN2 (CD112) and PVR (CD155), potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05073484 | Phase I | BAT6021 BAT1308 + BAT6021 | Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients | Terminated | AUS | 0 |